Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Эффективность ипидакрина в комплексной терапии диабетической полиневропатии
Эффективность ипидакрина в комплексной терапии диабетической полиневропатии
Зиновьева О.Е., Егоров П.Д., Пенкина А.И., Гусейнов С.С. Эффективность ипидакрина в комплексной терапии диабетической полиневропатии. Consilium Medicum. 2022;24(2):123–127.
DOI: 10.26442/20751753.2022.2.201554
DOI: 10.26442/20751753.2022.2.201554
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Диабетическая полиневропатия (ДПН) – частое неврологическое осложнение сахарного диабета. Наиболее распространенной клинической формой ДПН является дистальная симметричная, преимущественно сенсорная, полиневропатия (ДСПН), нередко сопровождающаяся болевым синдромом. Цель работы – оценить эффективность применения ипидакрина (Ипигрикса) в рамках комплексной терапии ДСПН. Динамика клинических и нейрофизиологических проявлений ДПН в виде появления ранее отсутствовавших сухожильных рефлексов, уменьшения зоны и выраженности сенсорных нарушений, интенсивности невропатической боли, увеличения амплитуды моторных и сенсорных ответов в ответ на стимуляцию периферических нервов свидетельствует об активации процессов реиннервации на фоне терапии с использованием ипидакрина. Оценивая положительный эффект в отношении восстановления структуры и функции периферических нервов, хорошую переносимость и безопасность ипидакрина (Ипигрикса), возможно рекомендовать применение препарата у пациентов с ДСПН.
Ключевые слова: сахарный диабет, диабетическая полиневропатия, диагностика, лечение, ипидакрин, реиннервация
and safety of ipidacrine (Ipigrix), it is possible to recommend the drug in patients with DSPN.
Keywords: diabetes mellitus, diabetic polyneuropathy, diagnostics, treatment, ipidacrine, reinnervation
Ключевые слова: сахарный диабет, диабетическая полиневропатия, диагностика, лечение, ипидакрин, реиннервация
________________________________________________
and safety of ipidacrine (Ipigrix), it is possible to recommend the drug in patients with DSPN.
Keywords: diabetes mellitus, diabetic polyneuropathy, diagnostics, treatment, ipidacrine, reinnervation
Полный текст
Список литературы
1. IDF Diabetes Atlas, 9th edition. Brussels: International Diabetes Federation, 2019. Available at: https://www.diabetesatlas.org/en. Accessed: 13.02.2022.
2. Neeland IJ, Patel KV. Diabetes: Key Markers of Injury and Prognosis. In: Biomarkers in Cardiovascular Disease. Ed. V Nambi. Netherlands: Elsevier, 2019; p. 41-51.
DOI:10.1016/B978-0-323-54835-9.00004-1
3. Hicks CW, Selvin E. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. Curr Diabetes Rep. 2019;19(10):86. DOI:10.1007/s11892-019-1212-8
4. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44 (Suppl. 1):S15-33. DOI:10.2337/dc21-S002
5. Маслова О.В., Сунцов Ю.И. Эпидемиология сахарного диабета и микрососудистых осложнений. Сахарный диабет. 2011;3:6-11 [Maslova OV, Suntsov YuI. Epidemiology of diabetes mellitus and microvascular complications. Diabetes mellitus. 2011;3:6-11 (in Russian)].
6. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285-93. DOI:10.2337/dc10-1303
7. Gordon SA, Singleton JR. Diabetic neuropathy. Continuum (Minneap Minn). 2012;18(1):60-84. DOI:10.1212/01.CON.0000411568.34085.3e
8. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43(4):817-24. DOI:10.1212/wnl.43.4.817
9. Зиновьева О.Е., Остроумова Т.М., Коняшова М.В., Горбачев Н.А. Диагностика и лечение поражений периферической нервной системы у пациентов с предиабетом. Неврология, нейропсихиатрия и психосоматика. 2021;13(5):116-22 [Zinovyeva OE, Ostroumova TM, Koniashova MV, Gorbachev NA. Evaluation and treatment of peripheral nervous system dysfunction in patients with prediabetes. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(5):116-22 (in Russian)].
10. Singleton JR, Smith AG, Russell J, Feldman EL. Polyneuropathy with Impaired Glucose Tolerance: Implications for Diagnosis and Therapy. Curr Treat Options Neurol. 2005;7(1):33-42. DOI:10.1007/s11940-005-0004-4
11. Ndip A, Ebah L, Mbako A. Neuropathic diabetic foot ulcers - evidence-to- practice. Int J Gen Med. 2012;5:129-34. DOI:10.2147/IJGM.S10328
12. Feldman EL, Stevens MJ, Thomas PK, et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17(11):1281-9. DOI:10.2337/diacare.17.11.1281
13. Herman WH, Pop-Busui R, Braffett BH, et al. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabet Med. 2012;29(7):937-44.
DOI:10.1111/j.1464-5491.2012.03644.x
14. Ziegler D, Papanas N, Zhivov A, et al. Early detection of nerve fiber loss by corneal confocal microscopy and skin biopsy in recently diagnosed type 2 diabetes. Diabetes. 2014;63(7):2454-63. DOI:10.2337/db13-1819
15. Tesfaye S, Vileikyte L, Rayman G, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27(7):629-38. DOI:10.1002/dmrr.1225
16. Figueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: the oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord. 2008;9(4):301-14. DOI:10.1007/s11154-008-9104-2
17. Yan LJ. Redox imbalance stress in diabetes mellitus: Role of the polyol pathway. Animal Model Exp Med. 2018;1(1):7-13. DOI:10.1002/ame2.12001
18. Park S, Kang HJ, Jeon JH, et al. Recent advances in the pathogenesis of microvascular complications in diabetes. Arch Pharm Res. 2019;42(3):252-62.
DOI:10.1007/s12272-019-01130-3
19. Nowotny K, Jung T, Höhn A, et al. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules. 2015;5(1):194-222. DOI:10.3390/biom5010194
20. Sugimoto K, Yasujima M, Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des. 2008;14(10):953-61. DOI:10.2174/138161208784139774
21. Kennedy JM, Zochodne DW. Impaired peripheral nerve regeneration in diabetes mellitus. J Peripher Nerv Syst. 2005;10(2):144-57. DOI:10.1111/j.1085-9489.2005.0010205.x
22. Sango K, Mizukami H, Horie H, Yagihashi S. Impaired Axonal Regeneration in Diabetes. Perspective on the Underlying Mechanism from In Vivo and In Vitro Experimental Studies. Front Endocrinol (Lausanne). 2017;8:12. DOI:10.3389/fendo.2017.00012
23. Leinninger GM, Vincent AM, Feldman EL. The role of growth factors in diabetic peripheral neuropathy. J Peripher Nerv Syst. 2004;9(1):26-53. DOI:10.1111/j.1085-9489.2004.09105.x
24. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med. 1995;122(8):561-8. DOI:10.7326/0003-4819-122-8-199504150-00001
25. Аметов А.С., Солуянова Т.Н. Преимущества бенфотиамина в лечении диабетической полинейропатии. Эффективная фармакотерапия в эндокринологии. 2008;1:1-4 [Ametov AS, Soluianova TN. Preimushchestva benfotiamina v lechenii diabeticheskoi polineiropatii. Effektivnaia farmakoterapiia v endokrinologii. 2008;1:1-4 (in Russian)].
26. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29(11):2365-70. DOI:10.2337/dc06-1216
27. Кукушкин М.Л., Карпова М.Н., Кузнецова Л.В., Клишина Н.Ю. Обезболивающее действие ипидакрина. Российский журнал боли. 2019;17(3):29-33 [Kukushkin ML, Karpova MN, Kuznetsova LV, Klishina NYu. Analgesic effect ipidacrine. Russian journal of pain. 2019;17(3):29-33 (in Russian)]. DOI:10.25731/RASP.2019.03.29
28. Строков И.А., Зиновьева О.Е., Баринов А.Н., Ахмеджанова Л.Т. Нейромидин в лечении диабетической полиневропатии. Неврологический журнал. 2007;12(6):52-5 [Strokov IA, Zinov'eva OE, Barinov AN, Akhmedzhanova LT. Neiromidin v lechenii diabeticheskoi polinevropatii. Nevrologicheskii zhurnal. 2007;12(6):52-5 (in Russian)].
29. Магомедова А.М., Меркулов Ю.А., Биглова А.Н., и др. Пациент с онемением в руках на амбулаторном приеме невролога: старые предрассудки, новые стратегии дифференциальной диагностики и лечения. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(3):16‑23 [Magomedova AM, Merkulov YA, Biglova AN, et al. An outpatient with hand numbness: old prejudices, new strategies of differential diagnosis and treatment. Zhurnal Nevrologii i Psikhiatrii im. SS Korsakova. 2019;119(3):16-23 (in Russian)]. DOI:10.17116/jnevro201911903116
30. Живолупов С.А., Самарцев И.Н. Нейропластичность: патофизиологические аспекты и возможности терапевтической модуляции. Журнал неврологии и психиатрии им. С.С. Корсакова. 2009;109(4):78-85 [Zhivolupov SA, Samartsev IN. Neuroplasticity: pathophysiological patterns and perspectives of therapeutic modulation. Zhurnal Nevrologii i Psikhiatrii Im. SS Korsakova. 2009;109(4):78-85 (in Russian)].
31. Катунина Е.А., Аванесова О.В., Пестовская О.Р., и др. Применение ингибиторов ацетилхолинэстеразы при лечении заболеваний периферической нервной системы. Фарматека. 2009;15:51-7 [Katunina EA, Avanesova OV, Pestovskaia OR, et al. Primenenie ingibitorov atsetilkholinesterazy pri lechenii zabolevanii perifericheskoi nervnoi sistemy. Farmateka. 2009;15:51-7 (in Russian)].
32. Рачин А.П., Шаров М.Н., Рачин С.А., Прокофьева Ю.С. Наблюдательное исследование по оценке эффективности применения препарата Ипигрикс при диабетической полиневропатии (исследование НИРВАНА). Нервные болезни. 2018;2:26-30 [Rachin AP, Sharov MN, Rachin SA, Prokof'eva IuS. Nabliudatel'noe issledovanie po otsenke effektivnosti primeneniia preparata Ipigriks pri diabeticheskoi polinevropatii (issledovanie NIRVANA). Nervnye bolezni. 2018;2:26-30
(in Russian)]. DOI:10.24411/2226-0757-2018-12019
2. Neeland IJ, Patel KV. Diabetes: Key Markers of Injury and Prognosis. In: Biomarkers in Cardiovascular Disease. Ed. V Nambi. Netherlands: Elsevier, 2019; p. 41-51.
DOI:10.1016/B978-0-323-54835-9.00004-1
3. Hicks CW, Selvin E. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. Curr Diabetes Rep. 2019;19(10):86. DOI:10.1007/s11892-019-1212-8
4. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44 (Suppl. 1):S15-33. DOI:10.2337/dc21-S002
5. Maslova OV, Suntsov YuI. Epidemiology of diabetes mellitus and microvascular complications. Diabetes mellitus. 2011;3:6-11 (in Russian).
6. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285-93. DOI:10.2337/dc10-1303
7. Gordon SA, Singleton JR. Diabetic neuropathy. Continuum (Minneap Minn). 2012;18(1):60-84. DOI:10.1212/01.CON.0000411568.34085.3e
8. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43(4):817-24. DOI:10.1212/wnl.43.4.817
9. Zinovyeva OE, Ostroumova TM, Koniashova MV, Gorbachev NA. Evaluation and treatment of peripheral nervous system dysfunction in patients with prediabetes. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(5):116-22 (in Russian).
10. Singleton JR, Smith AG, Russell J, Feldman EL. Polyneuropathy with Impaired Glucose Tolerance: Implications for Diagnosis and Therapy. Curr Treat Options Neurol. 2005;7(1):33-42. DOI:10.1007/s11940-005-0004-4
11. Ndip A, Ebah L, Mbako A. Neuropathic diabetic foot ulcers - evidence-to- practice. Int J Gen Med. 2012;5:129-34. DOI:10.2147/IJGM.S10328
12. Feldman EL, Stevens MJ, Thomas PK, et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17(11):1281-9. DOI:10.2337/diacare.17.11.1281
13. Herman WH, Pop-Busui R, Braffett BH, et al. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabet Med. 2012;29(7):937-44.
DOI:10.1111/j.1464-5491.2012.03644.x
14. Ziegler D, Papanas N, Zhivov A, et al. Early detection of nerve fiber loss by corneal confocal microscopy and skin biopsy in recently diagnosed type 2 diabetes. Diabetes. 2014;63(7):2454-63. DOI:10.2337/db13-1819
15. Tesfaye S, Vileikyte L, Rayman G, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27(7):629-38. DOI:10.1002/dmrr.1225
16. Figueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: the oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord. 2008;9(4):301-14. DOI:10.1007/s11154-008-9104-2
17. Yan LJ. Redox imbalance stress in diabetes mellitus: Role of the polyol pathway. Animal Model Exp Med. 2018;1(1):7-13. DOI:10.1002/ame2.12001
18. Park S, Kang HJ, Jeon JH, et al. Recent advances in the pathogenesis of microvascular complications in diabetes. Arch Pharm Res. 2019;42(3):252-62.
DOI:10.1007/s12272-019-01130-3
19. Nowotny K, Jung T, Höhn A, et al. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules. 2015;5(1):194-222. DOI:10.3390/biom5010194
20. Sugimoto K, Yasujima M, Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des. 2008;14(10):953-61. DOI:10.2174/138161208784139774
21. Kennedy JM, Zochodne DW. Impaired peripheral nerve regeneration in diabetes mellitus. J Peripher Nerv Syst. 2005;10(2):144-57. DOI:10.1111/j.1085-9489.2005.0010205.x
22. Sango K, Mizukami H, Horie H, Yagihashi S. Impaired Axonal Regeneration in Diabetes. Perspective on the Underlying Mechanism from In Vivo and In Vitro Experimental Studies. Front Endocrinol (Lausanne). 2017;8:12. DOI:10.3389/fendo.2017.00012
23. Leinninger GM, Vincent AM, Feldman EL. The role of growth factors in diabetic peripheral neuropathy. J Peripher Nerv Syst. 2004;9(1):26-53. DOI:10.1111/j.1085-9489.2004.09105.x
24. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med. 1995;122(8):561-8. DOI:10.7326/0003-4819-122-8-199504150-00001
25. Ametov AS, Soluianova TN. Preimushchestva benfotiamina v lechenii diabeticheskoi polineiropatii. Effektivnaia farmakoterapiia v endokrinologii. 2008;1:1-4 (in Russian).
26. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29(11):2365-70. DOI:10.2337/dc06-1216
27. Kukushkin ML, Karpova MN, Kuznetsova LV, Klishina NYu. Analgesic effect ipidacrine. Russian journal of pain. 2019;17(3):29-33 (in Russian). DOI:10.25731/RASP.2019.03.29
28. Strokov IA, Zinov'eva OE, Barinov AN, Akhmedzhanova LT. Neiromidin v lechenii diabeticheskoi polinevropatii. Nevrologicheskii zhurnal. 2007;12(6):52-5 (in Russian).
29. Magomedova AM, Merkulov YA, Biglova AN, et al. An outpatient with hand numbness: old prejudices, new strategies of differential diagnosis and treatment. Zhurnal Nevrologii i Psikhiatrii im. SS Korsakova. 2019;119(3):16-23 (in Russian). DOI:10.17116/jnevro201911903116
30. Zhivolupov SA, Samartsev IN. Neuroplasticity: pathophysiological patterns and perspectives of therapeutic modulation. Zhurnal Nevrologii i Psikhiatrii Im. SS Korsakova. 2009;109(4):78-85 (in Russian).
31. Katunina EA, Avanesova OV, Pestovskaia OR, et al. Primenenie ingibitorov atsetilkholinesterazy pri lechenii zabolevanii perifericheskoi nervnoi sistemy. Farmateka. 2009;15:51-7 (in Russian).
32. Rachin AP, Sharov MN, Rachin SA, Prokof'eva IuS. Nabliudatel'noe issledovanie po otsenke effektivnosti primeneniia preparata Ipigriks pri diabeticheskoi polinevropatii (issledovanie NIRVANA). Nervnye bolezni. 2018;2:26-30
(in Russian). DOI:10.24411/2226-0757-2018-12019
2. Neeland IJ, Patel KV. Diabetes: Key Markers of Injury and Prognosis. In: Biomarkers in Cardiovascular Disease. Ed. V Nambi. Netherlands: Elsevier, 2019; p. 41-51.
DOI:10.1016/B978-0-323-54835-9.00004-1
3. Hicks CW, Selvin E. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. Curr Diabetes Rep. 2019;19(10):86. DOI:10.1007/s11892-019-1212-8
4. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44 (Suppl. 1):S15-33. DOI:10.2337/dc21-S002
5. Маслова О.В., Сунцов Ю.И. Эпидемиология сахарного диабета и микрососудистых осложнений. Сахарный диабет. 2011;3:6-11 [Maslova OV, Suntsov YuI. Epidemiology of diabetes mellitus and microvascular complications. Diabetes mellitus. 2011;3:6-11 (in Russian)].
6. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285-93. DOI:10.2337/dc10-1303
7. Gordon SA, Singleton JR. Diabetic neuropathy. Continuum (Minneap Minn). 2012;18(1):60-84. DOI:10.1212/01.CON.0000411568.34085.3e
8. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43(4):817-24. DOI:10.1212/wnl.43.4.817
9. Зиновьева О.Е., Остроумова Т.М., Коняшова М.В., Горбачев Н.А. Диагностика и лечение поражений периферической нервной системы у пациентов с предиабетом. Неврология, нейропсихиатрия и психосоматика. 2021;13(5):116-22 [Zinovyeva OE, Ostroumova TM, Koniashova MV, Gorbachev NA. Evaluation and treatment of peripheral nervous system dysfunction in patients with prediabetes. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(5):116-22 (in Russian)].
10. Singleton JR, Smith AG, Russell J, Feldman EL. Polyneuropathy with Impaired Glucose Tolerance: Implications for Diagnosis and Therapy. Curr Treat Options Neurol. 2005;7(1):33-42. DOI:10.1007/s11940-005-0004-4
11. Ndip A, Ebah L, Mbako A. Neuropathic diabetic foot ulcers - evidence-to- practice. Int J Gen Med. 2012;5:129-34. DOI:10.2147/IJGM.S10328
12. Feldman EL, Stevens MJ, Thomas PK, et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17(11):1281-9. DOI:10.2337/diacare.17.11.1281
13. Herman WH, Pop-Busui R, Braffett BH, et al. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabet Med. 2012;29(7):937-44.
DOI:10.1111/j.1464-5491.2012.03644.x
14. Ziegler D, Papanas N, Zhivov A, et al. Early detection of nerve fiber loss by corneal confocal microscopy and skin biopsy in recently diagnosed type 2 diabetes. Diabetes. 2014;63(7):2454-63. DOI:10.2337/db13-1819
15. Tesfaye S, Vileikyte L, Rayman G, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27(7):629-38. DOI:10.1002/dmrr.1225
16. Figueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: the oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord. 2008;9(4):301-14. DOI:10.1007/s11154-008-9104-2
17. Yan LJ. Redox imbalance stress in diabetes mellitus: Role of the polyol pathway. Animal Model Exp Med. 2018;1(1):7-13. DOI:10.1002/ame2.12001
18. Park S, Kang HJ, Jeon JH, et al. Recent advances in the pathogenesis of microvascular complications in diabetes. Arch Pharm Res. 2019;42(3):252-62.
DOI:10.1007/s12272-019-01130-3
19. Nowotny K, Jung T, Höhn A, et al. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules. 2015;5(1):194-222. DOI:10.3390/biom5010194
20. Sugimoto K, Yasujima M, Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des. 2008;14(10):953-61. DOI:10.2174/138161208784139774
21. Kennedy JM, Zochodne DW. Impaired peripheral nerve regeneration in diabetes mellitus. J Peripher Nerv Syst. 2005;10(2):144-57. DOI:10.1111/j.1085-9489.2005.0010205.x
22. Sango K, Mizukami H, Horie H, Yagihashi S. Impaired Axonal Regeneration in Diabetes. Perspective on the Underlying Mechanism from In Vivo and In Vitro Experimental Studies. Front Endocrinol (Lausanne). 2017;8:12. DOI:10.3389/fendo.2017.00012
23. Leinninger GM, Vincent AM, Feldman EL. The role of growth factors in diabetic peripheral neuropathy. J Peripher Nerv Syst. 2004;9(1):26-53. DOI:10.1111/j.1085-9489.2004.09105.x
24. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med. 1995;122(8):561-8. DOI:10.7326/0003-4819-122-8-199504150-00001
25. Аметов А.С., Солуянова Т.Н. Преимущества бенфотиамина в лечении диабетической полинейропатии. Эффективная фармакотерапия в эндокринологии. 2008;1:1-4 [Ametov AS, Soluianova TN. Preimushchestva benfotiamina v lechenii diabeticheskoi polineiropatii. Effektivnaia farmakoterapiia v endokrinologii. 2008;1:1-4 (in Russian)].
26. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29(11):2365-70. DOI:10.2337/dc06-1216
27. Кукушкин М.Л., Карпова М.Н., Кузнецова Л.В., Клишина Н.Ю. Обезболивающее действие ипидакрина. Российский журнал боли. 2019;17(3):29-33 [Kukushkin ML, Karpova MN, Kuznetsova LV, Klishina NYu. Analgesic effect ipidacrine. Russian journal of pain. 2019;17(3):29-33 (in Russian)]. DOI:10.25731/RASP.2019.03.29
28. Строков И.А., Зиновьева О.Е., Баринов А.Н., Ахмеджанова Л.Т. Нейромидин в лечении диабетической полиневропатии. Неврологический журнал. 2007;12(6):52-5 [Strokov IA, Zinov'eva OE, Barinov AN, Akhmedzhanova LT. Neiromidin v lechenii diabeticheskoi polinevropatii. Nevrologicheskii zhurnal. 2007;12(6):52-5 (in Russian)].
29. Магомедова А.М., Меркулов Ю.А., Биглова А.Н., и др. Пациент с онемением в руках на амбулаторном приеме невролога: старые предрассудки, новые стратегии дифференциальной диагностики и лечения. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(3):16‑23 [Magomedova AM, Merkulov YA, Biglova AN, et al. An outpatient with hand numbness: old prejudices, new strategies of differential diagnosis and treatment. Zhurnal Nevrologii i Psikhiatrii im. SS Korsakova. 2019;119(3):16-23 (in Russian)]. DOI:10.17116/jnevro201911903116
30. Живолупов С.А., Самарцев И.Н. Нейропластичность: патофизиологические аспекты и возможности терапевтической модуляции. Журнал неврологии и психиатрии им. С.С. Корсакова. 2009;109(4):78-85 [Zhivolupov SA, Samartsev IN. Neuroplasticity: pathophysiological patterns and perspectives of therapeutic modulation. Zhurnal Nevrologii i Psikhiatrii Im. SS Korsakova. 2009;109(4):78-85 (in Russian)].
31. Катунина Е.А., Аванесова О.В., Пестовская О.Р., и др. Применение ингибиторов ацетилхолинэстеразы при лечении заболеваний периферической нервной системы. Фарматека. 2009;15:51-7 [Katunina EA, Avanesova OV, Pestovskaia OR, et al. Primenenie ingibitorov atsetilkholinesterazy pri lechenii zabolevanii perifericheskoi nervnoi sistemy. Farmateka. 2009;15:51-7 (in Russian)].
32. Рачин А.П., Шаров М.Н., Рачин С.А., Прокофьева Ю.С. Наблюдательное исследование по оценке эффективности применения препарата Ипигрикс при диабетической полиневропатии (исследование НИРВАНА). Нервные болезни. 2018;2:26-30 [Rachin AP, Sharov MN, Rachin SA, Prokof'eva IuS. Nabliudatel'noe issledovanie po otsenke effektivnosti primeneniia preparata Ipigriks pri diabeticheskoi polinevropatii (issledovanie NIRVANA). Nervnye bolezni. 2018;2:26-30
(in Russian)]. DOI:10.24411/2226-0757-2018-12019
________________________________________________
2. Neeland IJ, Patel KV. Diabetes: Key Markers of Injury and Prognosis. In: Biomarkers in Cardiovascular Disease. Ed. V Nambi. Netherlands: Elsevier, 2019; p. 41-51.
DOI:10.1016/B978-0-323-54835-9.00004-1
3. Hicks CW, Selvin E. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. Curr Diabetes Rep. 2019;19(10):86. DOI:10.1007/s11892-019-1212-8
4. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44 (Suppl. 1):S15-33. DOI:10.2337/dc21-S002
5. Maslova OV, Suntsov YuI. Epidemiology of diabetes mellitus and microvascular complications. Diabetes mellitus. 2011;3:6-11 (in Russian).
6. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285-93. DOI:10.2337/dc10-1303
7. Gordon SA, Singleton JR. Diabetic neuropathy. Continuum (Minneap Minn). 2012;18(1):60-84. DOI:10.1212/01.CON.0000411568.34085.3e
8. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43(4):817-24. DOI:10.1212/wnl.43.4.817
9. Zinovyeva OE, Ostroumova TM, Koniashova MV, Gorbachev NA. Evaluation and treatment of peripheral nervous system dysfunction in patients with prediabetes. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(5):116-22 (in Russian).
10. Singleton JR, Smith AG, Russell J, Feldman EL. Polyneuropathy with Impaired Glucose Tolerance: Implications for Diagnosis and Therapy. Curr Treat Options Neurol. 2005;7(1):33-42. DOI:10.1007/s11940-005-0004-4
11. Ndip A, Ebah L, Mbako A. Neuropathic diabetic foot ulcers - evidence-to- practice. Int J Gen Med. 2012;5:129-34. DOI:10.2147/IJGM.S10328
12. Feldman EL, Stevens MJ, Thomas PK, et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17(11):1281-9. DOI:10.2337/diacare.17.11.1281
13. Herman WH, Pop-Busui R, Braffett BH, et al. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabet Med. 2012;29(7):937-44.
DOI:10.1111/j.1464-5491.2012.03644.x
14. Ziegler D, Papanas N, Zhivov A, et al. Early detection of nerve fiber loss by corneal confocal microscopy and skin biopsy in recently diagnosed type 2 diabetes. Diabetes. 2014;63(7):2454-63. DOI:10.2337/db13-1819
15. Tesfaye S, Vileikyte L, Rayman G, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27(7):629-38. DOI:10.1002/dmrr.1225
16. Figueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: the oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord. 2008;9(4):301-14. DOI:10.1007/s11154-008-9104-2
17. Yan LJ. Redox imbalance stress in diabetes mellitus: Role of the polyol pathway. Animal Model Exp Med. 2018;1(1):7-13. DOI:10.1002/ame2.12001
18. Park S, Kang HJ, Jeon JH, et al. Recent advances in the pathogenesis of microvascular complications in diabetes. Arch Pharm Res. 2019;42(3):252-62.
DOI:10.1007/s12272-019-01130-3
19. Nowotny K, Jung T, Höhn A, et al. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules. 2015;5(1):194-222. DOI:10.3390/biom5010194
20. Sugimoto K, Yasujima M, Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des. 2008;14(10):953-61. DOI:10.2174/138161208784139774
21. Kennedy JM, Zochodne DW. Impaired peripheral nerve regeneration in diabetes mellitus. J Peripher Nerv Syst. 2005;10(2):144-57. DOI:10.1111/j.1085-9489.2005.0010205.x
22. Sango K, Mizukami H, Horie H, Yagihashi S. Impaired Axonal Regeneration in Diabetes. Perspective on the Underlying Mechanism from In Vivo and In Vitro Experimental Studies. Front Endocrinol (Lausanne). 2017;8:12. DOI:10.3389/fendo.2017.00012
23. Leinninger GM, Vincent AM, Feldman EL. The role of growth factors in diabetic peripheral neuropathy. J Peripher Nerv Syst. 2004;9(1):26-53. DOI:10.1111/j.1085-9489.2004.09105.x
24. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med. 1995;122(8):561-8. DOI:10.7326/0003-4819-122-8-199504150-00001
25. Ametov AS, Soluianova TN. Preimushchestva benfotiamina v lechenii diabeticheskoi polineiropatii. Effektivnaia farmakoterapiia v endokrinologii. 2008;1:1-4 (in Russian).
26. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29(11):2365-70. DOI:10.2337/dc06-1216
27. Kukushkin ML, Karpova MN, Kuznetsova LV, Klishina NYu. Analgesic effect ipidacrine. Russian journal of pain. 2019;17(3):29-33 (in Russian). DOI:10.25731/RASP.2019.03.29
28. Strokov IA, Zinov'eva OE, Barinov AN, Akhmedzhanova LT. Neiromidin v lechenii diabeticheskoi polinevropatii. Nevrologicheskii zhurnal. 2007;12(6):52-5 (in Russian).
29. Magomedova AM, Merkulov YA, Biglova AN, et al. An outpatient with hand numbness: old prejudices, new strategies of differential diagnosis and treatment. Zhurnal Nevrologii i Psikhiatrii im. SS Korsakova. 2019;119(3):16-23 (in Russian). DOI:10.17116/jnevro201911903116
30. Zhivolupov SA, Samartsev IN. Neuroplasticity: pathophysiological patterns and perspectives of therapeutic modulation. Zhurnal Nevrologii i Psikhiatrii Im. SS Korsakova. 2009;109(4):78-85 (in Russian).
31. Katunina EA, Avanesova OV, Pestovskaia OR, et al. Primenenie ingibitorov atsetilkholinesterazy pri lechenii zabolevanii perifericheskoi nervnoi sistemy. Farmateka. 2009;15:51-7 (in Russian).
32. Rachin AP, Sharov MN, Rachin SA, Prokof'eva IuS. Nabliudatel'noe issledovanie po otsenke effektivnosti primeneniia preparata Ipigriks pri diabeticheskoi polinevropatii (issledovanie NIRVANA). Nervnye bolezni. 2018;2:26-30
(in Russian). DOI:10.24411/2226-0757-2018-12019
Авторы
О.Е. Зиновьева, П.Д. Егоров*, А.И. Пенкина, С.С. Гусейнов
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*egorovpd@vk.com
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*egorovpd@vk.com
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*egorovpd@vk.com
________________________________________________
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*egorovpd@vk.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.